Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

32.91USD
2:00pm EST
Change (% chg)

$5.69 (+20.90%)
Prev Close
$27.22
Open
$30.60
Day's High
$33.85
Day's Low
$30.50
Volume
217,699
Avg. Vol
128,492
52-wk High
$41.83
52-wk Low
$24.48

EBS.N

Chart for EBS.N

About

Emergent BioSolutions Inc. is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of... (more)

Overall

Beta: 1.01
Market Cap(Mil.): $1,102.36
Shares Outstanding(Mil.): 40.50
Dividend: --
Yield (%): --

Financials

  EBS.N Industry Sector
P/E (TTM): 19.25 40.79 30.35
EPS (TTM): 1.41 -- --
ROI: 7.44 -0.56 15.27
ROE: 11.03 -1.20 16.60

BRIEF-Emergent Biosolutions Q3 adjusted EPS $0.58 from continuing operations

* Emergent biosolutions reports third quarter and nine months 2016 financial results

Nov 07 2016

BRIEF-Emergent biosolutions provides update on biothrax procurement contract and discussions with CDC

* Emergent Biosolutions provides update on status of Biothrax procurement contract and discussions with CDC

Sep 30 2016

BRIEF-Emergent awarded BARDA contract for advanced development of NuThrax

* Awarded BARDA contract for advanced development and delivery of NuThrax, a next generation anthrax vaccine, valued at up to $1.6 billion

Sep 30 2016

BRIEF-Emergent Biosolutions gets FDA approval for large-scale manufacturing of Biothrax in building 55

* Emergent Biosolutions receives FDA approval for large-scale manufacturing of Biothrax in building 55 Source text for Eikon: Further company coverage:

Aug 15 2016

BRIEF-Emergent announces conversion rate adjustment to 2.875% convertible senior notes

* Emergent biosolutions announces conversion rate adjustment to 2.875% convertible senior notes due 2021 following spin-off of aptevo therapeutics Source text for Eikon: Further company coverage:

Aug 12 2016

BRIEF-Emergent BioSolutions Q2 GAAP loss per share $0.27

* Emergent BioSolutions reports second quarter and six months 2016 financial results

Aug 04 2016

BRIEF-Emergent Biosolutions to repurchase shares for up to $50 mln

* Emergent Biosolutions to implement stock repurchase program for up to $50 million of its common stock

Jul 15 2016

BRIEF-FDA Accepts Emergent BioSolutions' supplemental biologics license application for large-scale manufacturing of BioThrax in Building 55

* FDA has set a prescription drug user fee act (PDUFA) target action date of august 15, 2016

Jun 17 2016

BRIEF-Emergent Biosolutions Inc receives FDA orphan drug status for BioThrax

* Emergent BioSolutions Inc receives FDA orphan drug status for BioThrax for post-exposure prophylaxis of anthrax disease

Jun 15 2016

Competitors

Earnings vs. Estimates